Thyroid Cancer: A Comprehensive Guide to Clinical Management | 3rd ed. 2016 Edition

Details about Thyroid Cancer: A Comprehensive Guide to Clinical Management:

Thoroughly revised and extensively expanded, this encyclopedic, highly acclaimed title addresses all aspects of the etiology, pathogenesis, diagnosis, initial treatment and long-term management of all varieties of thyroid cancer. Expertly edited by Drs. Leonard Wartofsky and Douglas Van Nostrand, this gold standard reference is divided into 11 Parts: General Considerations on Thyroid Cancer; General Considerations on Nuclear Medicine; the Thyroid Nodule; Well-Differentiated Thyroid Cancer; Variants of Thyroid Cancer, Undifferentiated Tumors: Medullary Thyroid Carcinoma; Undifferentiated Tumors: Thyroid Lymphoma; Undifferentiated Tumors: Anaplastic Thyroid Cancer; New Frontiers and Future Directions; and Additional Resources. With exceptional breadth and depth, the book includes chapters dedicated to isotopes, isotope uptake and scanning procedures such as SPECT/CT, radioiodine ablation (with or without recombinant human TSH), stunning, dosimetry (with or without recombinant human TSH), Octreotide and FDG-PET scanning and other alternative imaging modalities. There is a valuable reference atlas of scan images and illustrations, and a scholarly summary of the side effects of radioiodine and how to avoid or minimize adverse effects of treatment. In addition to an updated section on ultrasonography of the thyroid gland, new sections have been added, including ones on ultrasonography of cervical lymph nodes and imaging for thyroid cancer employing computerized tomography (CT), positron emission tomography (PET) and magnetic resonance imaging (MRI). An indispensable reference source with chapters written by the field’s leading authoritative experts, Thyroid Cancer: A Comprehensive Guide to Clinical Management, Third Edition, will be of great interest to not only pathologists, endocrine surgeons, endocrinologists, nuclear medicine physicians, and oncologists but all clinicians with an interest in thyroid cancer.